The reliability of tissue PD-L1 status alone as a predictive biomarker is affected by the inter-assay heterogeneity of tissue PD-L1 expression when different IHC assay platforms are employed (22), and by issues of tumor heterogeneity and intra-observer variability (23). The gene discussed is CD274; the disease is neoplasm.